Actively Recruiting
Epco, Zanu, Ritux for R/R FL or MZL
Led by Reid Merryman, MD · Updated on 2026-02-19
45
Participants Needed
3
Research Sites
266 weeks
Total Duration
On this page
Sponsors
R
Reid Merryman, MD
Lead Sponsor
B
BeiGene
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone lymphoma (MZL). * The names of the study drugs involved in this research study are: * Epcoritamab (a type of antibody) * Zanubrutinib (a type of Bruton tyrosine kinase inhibitor) * Rituximab (a type of monoclonal antibody)
CONDITIONS
Official Title
Epco, Zanu, Ritux for R/R FL or MZL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed diagnosis of CD20+ follicular lymphoma (grade 1-3A) or CD20+ marginal zone lymphoma (any subtype) at trial entry
- At least one prior line of therapy including a CD20 monoclonal antibody
- Measurable disease with at least one lesion or enlarged spleen based on imaging
- Meets at least one modified GELF criterion indicating need for treatment
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Age 18 years or older
- Adequate blood counts and organ function as specified
- Willingness and ability to provide informed consent
- Willingness to provide a pre-treatment tumor sample by biopsy
- Commitment to abstinence or use of two effective contraceptive methods during and after treatment as specified
You will not qualify if you...
- Requirement for systemic immunosuppressive therapy or prednisone dose over 10 mg daily
- Bulky cervical adenopathy compressing the airway
- Major surgery or significant injury within 4 weeks before study drug
- Presence of active hepatitis B or C infection without proper monitoring or treatment
- Active infections requiring antimicrobial therapy or recent significant infections
- Active COVID-19 infection or recent exposure without negative tests
- Prior history of other malignancies unless disease free for at least 2 years or low relapse risk
- Recent vaccination with live vaccines within specified timeframes
- Severe uncontrolled medical conditions affecting participation
- Significant cardiovascular conditions within 6 months or uncontrolled hypertension
- Pregnancy, breastfeeding, or intention to become pregnant
- Prior solid organ or allogeneic stem cell transplantation
- History of hemophagocytic lymphohistiocytosis or significant autoimmune diseases
- Allergy or intolerance to study drugs
- Known central nervous system involvement
- Neuropathy greater than grade 1
- Prior CAR-T therapy within 100 days
- Recent investigational drugs or chemotherapy within 4 weeks
- Use of warfarin or vitamin K antagonists
- Use of strong CYP3A inducers
- Inability to swallow capsules or significant gastrointestinal issues
- Severe bleeding disorders requiring ongoing warfarin
- Prior exposure to a BTK inhibitor
- Limit on patients with bispecific antibody-refractory disease
- Screening ECG with QTcF over 480 msec
- History of stroke or intracranial hemorrhage within 6 months
- Major surgery within 4 weeks before first dose or planned during study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
2
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10021
Actively Recruiting
3
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States, 43210
Actively Recruiting
Research Team
R
Reid Merryman, MD
CONTACT
H
Heather A Walker, MPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here